miR-17-5p在大鼠垂体泌乳素腺瘤MMQ细胞耐药中的作用

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1531 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the roles of microRNA-17-5p may play in the resistance of MMQ cells to dopamine agonists. Methods: MMQ cells were either treated with miR-17-5p mimics or miR-17-5p inhibitor to regulate the expression of miR-17-5p in vitro qPCR was used to verify the transfection efficiency. After treatment, cell viability and its response to CAB was determined with CCK-8 assays. The target gene of miR-17-5p was predicted and confirmed via bioinformatics analysis and luciferase reporter assays. The expression of PTEN was analyzed by qPCR and Western Blotting. In addition we deployed CCK-8 assay to evaluate the response to CAB of MMQ cells which were initially treated with lentiviral vector containing PTEN. Results: Overexpression of miR-17-5p could promote the proliferation of MMQ cells and suppress CAB cytotoxicity. On the contrary, down-regulated of the expression of miR-17-5p could effectively inhibit proliferation and boost susceptibility to CAB in MMQ cells. The bioinformatics database identified the potential target of miR-17-5p and the luciferase reporter assay confirmed that PTEN was the direct target of miR-17-5p. While the expression of PTEN was down-regulated in miR-17-5p over-expressed MMQ cells, the expression of PTEN was up-regulated in miR-17-5p knockdown MMQ cells. Furthermore, PTEN over-expression was able to reverse the drug resistance induced by miR-17-5p on CAB treatment. Conclusion: miR-17-5p promotes MMQ proliferation and mediates CAB resistance by targeting PTEN.

Key words： microRNA-17-5p prolactinoma cabergoline PTEN rats

Received: 21 December 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUAN Jiaqing
	XU Jiadong
	WANG Chunyong
	SU Zhipeng
	CAI Lin
	CHEN Xianbin
	ZHENG Weiming

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I4/258

[1] GILLAM M P, MOLITCH M E, LOMBARDI G, et al. Advances in the treatment of prolactinomas[J]. Endocr Rev, 2006, 27(5): 485-534.
[2] WU Z B, YU C J, SU Z P, et al. Bromocriptine treatment of invasive giant prolactinomas involving the cavernoussinus: results of a long-term follow up[J]. J Neurosurg, 2006, 104(1): 54-61.
[3] COLAO A, DI SARNO A, GUERRA E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy[J]. Clin Endocrinol (Oxf), 2007, 67(3): 426-433.
[4] MOLITCH M E. Pituitary gland: can prolactinomas be cured medically?[J]. Nat Rev Endocrinol, 2010, 6(4): 186-188.
[5] WU Z R, ZHANG Y, CAI L, et al. Long-term clinical outcomes of invasive giant prolactinomas after a mean ten-year followup[J]. Int J Endocrinol, 2016, 2016: 8580750.
[6] MOLITCH M E. Dopamine resistance of prolactinomas[J]. Pituitary, 2003, 6(1): 19-27.
[7] ADAMS B D, PARSONS C, WALKER L, et al. Targeting noncoding RNAs in disease[J]. J Clin Invest, 2017, 127(3): 761-771.
[8] ZENG H C, BAE Y, DAWSON B C, et al. MicroRNA miR-23a cluster promotes osteocyte differentiation by regulating TGF-beta signalling in osteoblasts[J]. Nat Commun, 2017, 8: 15000.
[9] ZHANG W, XU J, SHI Y, et al. The novel role of miRNAs for tamoxifen resistance in human breast cancer[J]. Cell Mol Life Sci, 2015, 72(13): 2575-2584.
[10] DUAN Z, GAO Y, SHEN J, et al. MiR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo [J]. Mol Oncol, 2017, 11(2): 151-166.
[11] NEESSE A, GRESS T M. Emerging role of microRNAs to tackle drug resistance in pancreatic cancer[J]. Gut, 2015, 64(12): 1842-1843.
[12] AHMAD N, HAIDER S, JAGANNATHAN S, et al. MicroRNA theragnostics for the clinical management of multiple myeloma[J]. Leukemia, 2014, 28(4): 732-738.
[13] FANINI F, FABBRI M. MicroRNAs and cancer resistance: a new molecular plot[J]. Clin Pharmacol Ther, 2016, 99(5): 485-493.
[14] XI X P, ZHUANG J, TENG M J, et al. MicroRNA-17 induces epithelial-mesenchymal transition consistent with the cancer stem cell phenotype by regulating CYP7B1 expression in colon cancer[J]. Int J Mol Med, 2016, 38(2): 499-506.
[15] WU Z B, LI W Q, LIN S J, et al. MicroRNA expression profile of bromocriptine-resistant prolactinomas[J]. Mol Cell Endocrinol, 2014,395(1-2):10-18.
[16] 赵晓蕾, 蔡林, 邓洲铭. microRNA与骨肉瘤的研究进展[J].中国骨与关节杂志, 2014, 3(10): 773-778.
[17] JIA J G, ZHAN D K, LI J, et al. The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells [J]. J Cell Mol Med, 2018, 23(1): 656-669.
[18] SAEED NOOROLYAI, AHAD MOKHTARZADEH, ELHAM BAGHBANI, et al. The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer[J]. J Cell Physiol, 2018, 2018: 1-10.
[19] TSUGAWA K, JONES M K, SUGIMACHI K, et al. Biological role of phosphatase PTEN in cancer and tissue injury healing[J]. Front Biosci, 2002, 7: e245-251.
[20] RAFTOPOULOU M, ETIENNE-MANNEVILLE S, SELF A, et al. Regulation of cell migration by the C2 domain of the tumor suppressor PScience TEN[J]. Science, 2004, 303(5661): 1179-1181.
[21] GILDEA J J, HERLEVSEN M, HARDING M A, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity[J]. Oncogene, 2004, 23(40): 6788-6797.
[22] HU Y, XU S, JIN W, et al. Effect of the PTEN gene on adhesion, invasion and metastasis of osteosarcoma cells[J]. Oncol Rep, 2014, 32(4): 1741-1747.
[23] CHEN MW, WU XJ. SLC25A22 promotes proliferation and metastasis of osteosarcoma cells via the PTEN signaling pathway [J]. Technol Cancer Res Trest, 2018, 17: 1533033818811143.
[24] TIAN K, DI R, WANG L. MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma[J]. Cancer Gene Ther, 2015, 22(7): 351-359.
[25] 金晓昇, 安慧敏, 黄智铭. 生存素和PTEN在良恶性胃溃疡中的表达[J]. 温州医科大学学报, 2017, 47(6): 456-458.c